Abstract: Key figures of the sector demonstrate that the pharmaceutical
companies play a pivotal role in health research, in terms of resources and
investments. Despite these efforts, only 1 substance out of 5–10.000
successfully passes the necessary tests, and 2 drugs out of 10 can defray
R&D costs . This inevitably leads to the need of new R&D
models which may include more focused clinical studies with e-designed
mechanisms (Fig. 1) and open source protection of intellectual property.
Innovation is also expected to boost the research environment and the
pharmaceutical industries are responding by outsourcing and buyout biotech
companies, with investing only 20% in in-house research . In the Italian
environment an integrated approach for the formation of a public-private
network with pharmaceutical and biotech companies, public R&D
institutions and universities, with patient and non-profit organisation is
believed to be the key for success by offering the possibility to link internal
excellence to the international research network.